Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Volasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 17/20 | 1.00 |
| ▸ | BRD4 | O60885 | 12/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 4/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 4/20 | 1.00 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 1.00 |
| ▸ | PDXK | O00764 | 2/20 | 1.00 |
| ▸ | NEK3 | P51956 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
| ▸ | WEE1 | P30291 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.64 |
| ▸ | CLK2 | P49760 | 3/20 | 0.64 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.64 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.64 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.64 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.64 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.64 |
| ▸ | PRKCG | P05129 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Volasertib SCHEMBL2169101 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL16984415 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL30753526 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL9888052 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL18636896 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL14136759 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL29363620 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL18636919 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL21916558 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL29644957 | 0.99 | PLK1 (0.99) | PLK1BRD4PLK3PTK2BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073350-A1 | Method for Preparing Volasertib and Intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-16 | — | — | US | claimed |
| EP-3098223-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2016-11-30 | — | — | EP | claimed |
| US-8664222-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-04 | — | — | US | claimed |
| EP-2543669-A2 | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation | Boehringer Ingelheim International GmbH (DE) | 2013-01-09 | — | — | EP | claimed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | claimed |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | claimed |
| US-8188086-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | claimed |
| EP-2340837-A1 | Combination treatment of cancer comprising EGFR/HER2 inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-06 | — | — | EP | claimed |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | claimed |
| EP-2185559-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-05-19 | — | — | EP | claimed |
| US-20090306101-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | claimed |
| WO-2009019205-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | claimed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | claimed |
| EP-1984367-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-29 | — | — | EP | claimed |
| US-7439358-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | claimed |
| EP-1948180-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-07-30 | — | — | EP | claimed |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | ONCOHEROES BIOSCIENCES INC. | 2007-08-30 | — | — | US | claimed |
| WO-2007090844-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | WO | claimed |
| WO-2007054551-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-18 | — | — | WO | claimed |
| US-12622911-B2 | Methods and compositions for the treatment of pulmonary fibrosis using volasertib | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-05-12 | — | — | US | disclosed |
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | BRYET US, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-08-24 | — | — | US | disclosed |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230127861-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS USING VOLASERTIB | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-04-27 | — | — | US | disclosed |
| US-20230127861-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS USING VOLASERTIB | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-04-27 | — | — | US | disclosed |
| US-20230103366-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-04-06 | — | — | US | disclosed |
| US-11583536-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | disclosed |
| WO-2021262962-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-2914296-B2 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2021080955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210113576-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2021-04-22 | — | — | US | disclosed |
| US-10980804-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210038602-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-20210038602-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-20210030771-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-02-04 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10772898-B2 | Combination therapies and methods of use thereof for treating cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3003309-B1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111629725-A | Combination therapy for acute myeloid leukemia | 勃林格殷格翰国际有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190290652-A1 | METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES | ONCOHEROES BIOSCIENCES INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190240241-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME I | BOEHRINGER INGELHEIM INT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190240242-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | BOEHRINGER INGELHEIM INT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190240241-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME I | BOEHRINGER INGELHEIM INT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190125765-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2019-05-02 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| EP-2914296-B1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9956225-B2 | Treatment of myelodysplastic syndrome | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-01 | — | — | US | disclosed |
| US-20180086744-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-9867831-B2 | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3200879-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME III | Boehringer Ingelheim International GmbH & Co. KG (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-20170216317-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-08-03 | — | — | US | disclosed |
| US-9688685-B2 | Method for preparing volasertib and intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-06-27 | — | — | US | disclosed |
| US-9688685-B2 | Method for preparing volasertib and intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-06-27 | — | — | US | disclosed |
| US-20170173023-A1 | COMBINATION THERAPY WITH VOLASERTIB | BOEHRINGER INGELHEIM INT (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170157159-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME I | BOEHRINGER INGELHEIM INT (DE) | 2017-06-08 | — | — | US | disclosed |
| US-20170157159-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME I | BOEHRINGER INGELHEIM INT (DE) | 2017-06-08 | — | — | US | disclosed |
| US-20170157158-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | BOEHRINGER INGELHEIM INT (DE) | 2017-06-08 | — | — | US | disclosed |
| US-20170157158-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | BOEHRINGER INGELHEIM INT (DE) | 2017-06-08 | — | — | US | disclosed |
| US-20170073350-A1 | Method for Preparing Volasertib and Intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-20170073350-A1 | Method for Preparing Volasertib and Intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-9566280-B2 | Combination therapies and methods of use thereof for treating cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567641-B2 | Combination therapy for the treatment of cancer using an anti-C-met antibody | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-02-14 | — | — | US | disclosed |
| EP-2707001-B1 | METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES | BOEHRINGER INGELHEIM INT (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| EP-3098223-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2016-11-30 | — | — | EP | disclosed |
| EP-3098223-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2016-11-30 | — | — | EP | disclosed |
| US-20160303131-A1 | METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160243124-A1 | METHOD FOR TREATING ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INT (DE) | 2016-08-25 | — | — | US | disclosed |
| US-9370535-B2 | Method for treatment of advanced solid tumors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-21 | — | — | US | disclosed |
| US-9358233-B2 | Method for treating acute myeloid leukemia | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| EP-3024464-A1 | TREATMENT OF MYELODYSPLASTIC SYNDROME | Boehringer Ingelheim International GmbH (DE) | 2016-06-01 | — | — | EP | disclosed |
| EP-3024488-A1 | VOLASERTIB IN COMBINATION WITH AZACITIDINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | Boehringer Ingelheim International GmbH (DE) | 2016-06-01 | — | — | EP | disclosed |
| EP-3024465-A1 | VOLASERTIB IN COMBINATION WITH DECITABINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | Boehringer Ingelheim International GmbH (DE) | 2016-06-01 | — | — | EP | disclosed |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160095863-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA and MYELODYSPLASTIC SYNDROME | ONCOHEROES BIOSCIENCES INC., | 2016-04-07 | — | — | US | disclosed |
| WO-2016050749-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME III | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-07 | — | — | WO | disclosed |
| US-20160024051-A1 | SALTS AND SOLID FORMS OF ISOQUINOLINONES AND COMPOSITION COMPRISING AND METHODS OF USING THE SAME | INFINITY PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20150366866-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2925343-A1 | COMBINATION THERAPY WITH VOLASERTIB | Boehringer Ingelheim International GmbH (DE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2015117055-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150209359-A1 | Combination Therapies and Methods of Use Thereof for Treating Cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2015-07-30 | — | — | US | disclosed |
| WO-2015011234-A1 | VOLASERTIB IN COMBINATION WITH DECITABINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-29 | — | — | WO | disclosed |
| US-20150031699-A1 | TREATMENT OF MYELODYSPLASTIC SYNDROME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| WO-2015011235-A1 | VOLASERTIB IN COMBINATION WITH AZACITIDINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015011236-A1 | TREATMENT OF MYELODYSPLASTIC SYNDROME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-29 | — | — | WO | disclosed |
| US-20150031643-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20150010575-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING AN ANTI-C-MET ANTIBODY | GEORGETOWN UNIVERSITY | 2015-01-08 | — | — | US | disclosed |
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| CN-102093360-B | Process for preparing a dihydropteridinone derivative | BOEHRINGER INGELHEIM INT | 2014-11-05 | — | — | CN | disclosed |
| US-20140199298-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-17 | — | — | US | disclosed |
| US-20140154304-A1 | COMBINATION THERAPY WITH VOLASERTIB | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| WO-2014083058-A1 | COMBINATION THERAPY WITH VOLASERTIB | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-05 | — | — | WO | disclosed |
| EP-2709626-A1 | METHOD FOR TREATMENT OF ADVANCED SOLID TUMORS | Boehringer Ingelheim International GmbH (DE) | 2014-03-26 | — | — | EP | disclosed |
| EP-2707001-A1 | METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES | Boehringer Ingelheim International GmbH (DE) | 2014-03-19 | — | — | EP | disclosed |
| US-8664222-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664222-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664222-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664222-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| EP-2646033-A1 | VOLASERTIB ALONE OR IN COMBINATION WITH CYTARABINE FOR TREATING ACUTE MYELOID LEUKEMIA | Boehringer Ingelheim International GmbH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-8546566-B2 | Process for manufacturing dihydropteridinones and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546566-B2 | Process for manufacturing dihydropteridinones and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130131069-A1 | METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-8445675-B2 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20130122111-A1 | METHOD FOR TREATMENT OF ADVANCED SOLID TUMORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| EP-2543669-A3 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| EP-2543669-A2 | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation | Boehringer Ingelheim International GmbH (DE) | 2013-01-09 | — | — | EP | disclosed |
| EP-2543669-A2 | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation | Boehringer Ingelheim International GmbH (DE) | 2013-01-09 | — | — | EP | disclosed |
| EP-2543669-A2 | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation | Boehringer Ingelheim International GmbH (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329704-B2 | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-12-11 | — | — | US | disclosed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120295864-A1 | METHOD FOR TREATING ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012156380-A1 | METHOD FOR TREATMENT OF ADVANCED SOLID TUMORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012156283-A1 | METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | WO | disclosed |
| US-20120238754-A1 | Process for manufacturing dihydropteridinones and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238754-A1 | Process for manufacturing dihydropteridinones and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012072505-A1 | VOLASERTIB ALONE OR IN COMBINATION WITH CYTARABINE FOR TREATING ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| US-8188086-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8188086-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8188086-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8188086-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8138341-B2 | Intermediate compounds useful for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138341-B2 | Intermediate compounds useful for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138373-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138373-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| CN-101379064-B | Trihydrochloride forms of dihydropteridinone derivatives and process for their preparation | BOEHRINGER INGELHEIM INT | 2012-01-25 | — | — | CN | disclosed |
| EP-1778238-B1 | DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE | BOEHRINGER INGELHEIM INT (DE) | 2011-10-12 | — | — | EP | disclosed |
| EP-2340837-A1 | Combination treatment of cancer comprising EGFR/HER2 inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-06 | — | — | EP | disclosed |
| CN-102093360-A | Process for preparing a dihydropteridinone derivative | BOEHRINGER INGELHEIM INT | 2011-06-15 | — | — | CN | disclosed |
| WO-2006018221-A9 | DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249412-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249412-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-7759485-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759485-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| EP-2185559-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-05-19 | — | — | EP | disclosed |
| EP-2185559-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-05-19 | — | — | EP | disclosed |
| US-20090306101-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| CN-101379064-A | Trihydrochloride forms of dihydropteridinone derivatives and process for their preparation | BOEHRINGER INGELHEIM INT (DE) | 2009-03-04 | — | — | CN | disclosed |
| WO-2009019205-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019205-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1984367-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1984367-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-29 | — | — | EP | disclosed |
| US-7439358-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-7439358-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-7439358-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-7439358-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| EP-1948180-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| WO-2007090844-A8 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2007-10-11 | — | — | WO | disclosed |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | ONCOHEROES BIOSCIENCES INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | ONCOHEROES BIOSCIENCES INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | ONCOHEROES BIOSCIENCES INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | ONCOHEROES BIOSCIENCES INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007090844-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090844-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090844-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007054551-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103366-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | PLK2, KLK3, PLK3 | PLK1 6/4885BRD4 2275/4885PLK3 3/4885 |
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | PIK3CA, MCL1, PIK3CB | PLK1 49/4885BRD4 1099/4885PLK3 359/4885 |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | HCCS, PNLIP, LIPA | PLK1 119/4885BRD4 401/4885PLK3 1069/4885 |
| US-20210038602-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BRD4, MCL1, BET1 | PLK1 213/4885BRD4 1/4885PLK3 1446/4885 |
| US-10980804-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | PLK1 119/4885BRD4 401/4885PLK3 1069/4885 |
| US-20150031699-A1 | TREATMENT OF MYELODYSPLASTIC SYNDROME | MCL1, JAK2, VHL | PLK1 57/4885BRD4 713/4885PLK3 527/4885 |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | PLK1 2334/4885BRD4 4860/4885PLK3 2069/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | PLK1 121/4885BRD4 205/4885PLK3 1191/4885 |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | PLK1 16/4885BRD4 10/4885PLK3 590/4885 |
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | PLK2, PLK4, PLK1 | PLK1 3/4885BRD4 988/4885PLK3 10/4885 |
| US-20210113576-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | PLK1 19/4885BRD4 13/4885PLK3 501/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PLK1 121/4885BRD4 205/4885PLK3 1191/4885 |
| US-20190290652-A1 | METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES | BRAF, PLK1, KRAS | PLK1 2/4885BRD4 384/4885PLK3 272/4885 |
| US-20160095863-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA and MYELODYSPLASTIC SYNDROME | MCL1, FLT3, JAK2 | PLK1 66/4885BRD4 149/4885PLK3 469/4885 |
| US-20190240241-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME I | MCL1, FLT3, DNMT3A | PLK1 134/4885BRD4 210/4885PLK3 756/4885 |
| US-20140199298-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | EGFR, ERBB2, ERBB3 | PLK1 433/4885BRD4 1032/4885PLK3 3635/4885 |
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | MSN, CD47, CTTN | PLK1 304/4885BRD4 4644/4885PLK3 3751/4885 |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, REN, DHPS | PLK1 2489/4885BRD4 645/4885PLK3 1248/4885 |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, DHPS, DPYD | PLK1 3099/4885BRD4 2295/4885PLK3 1986/4885 |
| US-20170173023-A1 | COMBINATION THERAPY WITH VOLASERTIB | MCL1, CSF3R, KIT | PLK1 35/4885BRD4 777/4885PLK3 651/4885 |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | DHPS, PKD1, AQP4 | PLK1 2690/4885BRD4 453/4885PLK3 713/4885 |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | PLK4, PLK2, BUB1B | PLK1 5/4885BRD4 1076/4885PLK3 4/4885 |
| US-20150010575-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING AN ANTI-C-MET ANTIBODY | MET, HGF, HGFAC | PLK1 1994/4885BRD4 2671/4885PLK3 3318/4885 |
| US-20150209359-A1 | Combination Therapies and Methods of Use Thereof for Treating Cancer | PLK2, KLK3, PLK3 | PLK1 6/4885BRD4 2275/4885PLK3 3/4885 |
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | PLK1 4737/4885BRD4 4869/4885PLK3 4120/4885 |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | PLK1 2334/4885BRD4 4860/4885PLK3 2069/4885 |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | NEK1, NEK11, CDK9 | PLK1 16/4885BRD4 12/4885PLK3 324/4885 |
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | PLK1 2859/4885BRD4 2/4885PLK3 2255/4885 |
| US-20170216317-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | PLK2, KLK3, PLK3 | PLK1 6/4885BRD4 2275/4885PLK3 3/4885 |
| US-12622911-B2 | Methods and compositions for the treatment of pulmonary fibrosis using volasertib | PLK1, MMP1, DSP | PLK1 1/4885BRD4 316/4885PLK3 74/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PLK1 121/4885BRD4 205/4885PLK3 1191/4885 |
| US-20150031643-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | MCL1, FLT3, JAK2 | PLK1 138/4885BRD4 172/4885PLK3 1039/4885 |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | PLK1 1/4885BRD4 903/4885PLK3 112/4885 |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, PIK3CG, PIK3CD | PLK1 276/4885BRD4 1751/4885PLK3 363/4885 |
| US-20160243124-A1 | METHOD FOR TREATING ACUTE MYELOID LEUKEMIA | MCL1, FLT3, BRD7 | PLK1 184/4885BRD4 57/4885PLK3 1559/4885 |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | PLK1 4737/4885BRD4 4869/4885PLK3 4120/4885 |
| US-20130122111-A1 | METHOD FOR TREATMENT OF ADVANCED SOLID TUMORS | VHL, PLK1, TP53 | PLK1 2/4885BRD4 261/4885PLK3 150/4885 |
| US-20170157158-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II | MCL1, FLT3, JAK2 | PLK1 138/4885BRD4 172/4885PLK3 1039/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | PLK1 1/4885BRD4 903/4885PLK3 112/4885 |
| US-10772898-B2 | Combination therapies and methods of use thereof for treating cancer | PLK2, KLK3, PLK3 | PLK1 6/4885BRD4 2275/4885PLK3 3/4885 |
| US-20180086744-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | EGFR, ERBB2, ERBB3 | PLK1 433/4885BRD4 1032/4885PLK3 3635/4885 |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | QDPR, F5, F12 | PLK1 2334/4885BRD4 4860/4885PLK3 2069/4885 |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PLK1 49/4885BRD4 1099/4885PLK3 359/4885 |
| US-20120238754-A1 | Process for manufacturing dihydropteridinones and intermediates thereof | DHPS, QDPR, CYP4F12 | PLK1 4389/4885BRD4 4668/4885PLK3 3949/4885 |
| US-20230127861-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS USING VOLASERTIB | MMP1, MMP8, FIBP | PLK1 141/4885BRD4 344/4885PLK3 697/4885 |
| US-20170073350-A1 | Method for Preparing Volasertib and Intermediate thereof | CDK8, MDK, WEE1 | PLK1 14/4885BRD4 535/4885PLK3 542/4885 |
| US-11583536-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | PLK1 19/4885BRD4 13/4885PLK3 501/4885 |
| US-20130131069-A1 | METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES | BRAF, PLK1, KRAS | PLK1 2/4885BRD4 384/4885PLK3 272/4885 |
| US-20090306101-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | EGFR, ERBB2, ERBB3 | PLK1 391/4885BRD4 1015/4885PLK3 3508/4885 |
| US-20140154304-A1 | COMBINATION THERAPY WITH VOLASERTIB | MCL1, CSF3R, KIT | PLK1 35/4885BRD4 777/4885PLK3 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.